header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

RE-REVISION OF THE FEMORAL COMPONENT IN PATIENTS WITH OSTEONECROSIS



Abstract

Introduction: In a previous study (ARCO, 2002), we reported that the clinical results of revision total hip arthroplasty for osteonecrosis patients were less satisfactory than those found for a matched group of osteoarthritis patients. The aim of this study was to evaluate the potential factors that may have contributed to these findings.

Materials and Methods: This study included 34 hips in 30 osteonecrosis patients who had undergone revision of a femoral total hip arthroplasty component. There were 19 men (22 hips) and 11 women (12 hips) who had a mean age of 46.1 years (range, 28 to 69 years). The surgeries were performed between March 1984 and January 2001. Most femoral stems (91%) were implanted without cement. Prostheses were of different stem lengths, but most (97%) were proximally porous-coated. The mean follow-up was 8.2 years [range, 0.1 (a re-revision) to 19.8 years]. A physical examination as well as patient and physician outcome forms were collected at each visit. Preoperative x-rays were categorized according to the technique of Della Valle and Paprosky. A Kaplan-Meier survival analysis was performed (PEPI statistical software package).

Results: Risk factors for osteonecrosis included 15 corticosteroid, 8 alcohol, 7 trauma, and 4 unknown. This was the first revision in 27 cases, second revision in 5 cases, and third revision in 2 cases. Preoperatively, the defects included 4 Type I, 9 Type II, 15 Type IIIA, 2 Type IIIB, 1 Type IV, and 3 unknown types. Of the 34 hips, the femoral component was re-revised in 12 cases. One of the failures was the only fully porous coated stem that was implanted. One of the 3 cemented implants failed, as compared to 11 of the 31 implanted without cement. Survival rates were 90.9% (74.4%–97.1%) at 5 years, 54.8% (24.9%–81.6%) at 10 years, 54.8% (19.9%–85.6%) at 15 years, and 27.4% (1.7%–88.9%) at 20 years. There was no relationship between frequency of re-revision and defect category, risk factors, or age.

Discussion: Although there was a high failure rate (12/34; 34%) in this patient cohort, over 50% survived at least 10–15 years. The lack of a relationship between the patient age or the extent of defect and re-revision suggest that other factors concerning this disease need to be examined.

Editorial Secretaries: Lynne C. Jones, Ph.D.* and Michael A. Mont, M.D. Address for Correspondence: *Lynne C. Jones, Ph.D., Suite 201 GSH POB, 5601 Loch Raven Blvd., Baltimore, MD 21239, USA. Email: ljones3@jhmi.edu